France's Inventiva H1 net loss narrows

Inventiva SA

28/09/2026 07:12

Overview
Net loss for H1 2026 narrowed to €69.5 mln from €175.9 mln in prior year
Company increased R&D and G&A expenses, driven by clinical development and pre-commercial activities

Outlook
Inventiva expects topline results from Phase 3 NATiV3 trial in Q4 2026
Company maintains cash runway guidance to end of Q2 2027
Cash runway could extend to early Q1 2028 if additional financing is secured

Result Drivers
NO LICENSE REVENUE - Co recorded no revenue in H1 2026, as prior-year revenue was attributable to a licensing agreement with Chia Tai Tianging
R&D SPENDING - Higher R&D expenses driven by clinical development of lanifibranor for MASH
PRE-COMMERCIAL COSTS - Increased marketing and G&A expenses reflect preparations for potential commercial launch of lanifibranor

Company press release: ID:nGNE85fBvM

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 20,000
 
H1 Loss Per Share
 
EUR 0.25
 
H1 Net Loss
 
EUR 69.47 mln
 
H1 Operating Income
 
-EUR 70.39 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Inventiva SA is €10.47, about 267.9% above its September 25 closing price of €2.85

Reuters Recommended Reads
Sept 25 - ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO
Sept 25 - US FDA approves Mirum's drug for rare bone disorder
Sept 25 - Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)